![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/19664437-667504421-nkarta-logo-2022-jpg-100x26.jpeg)
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned …